Anjalee Khemlani

    Senior Reporter

    Anjalee Khemlani is an award-winning healthcare and business reporter at Yahoo Finance covering the entire healthcare sector, including pharma, health tech, providers, insurers, PBMs and health equity. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio, and has been a guest on global broadcast and radio stations covering the Covid-19 pandemic and global public health.

  • Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market

    Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.

  • Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy

    Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.

  • Walgreens partners with Boehringer Ingelheim for clinical trials

    Walgreens is ramping up its clinical trial offerings with Big Pharma players.

  • Pfizer stock gains 7% after earnings beat, company calls dividend 'secure'

    Pfizer had a surprise beat in its COVID portfolio despite dim forecasts, but the company is still not feeling the love in its stock.

  • CVS stock plunges after earnings numbers one analyst 'did not even believe'

    CVS warns it could cede Medicare Advantage market share as reimbursement rates pressure the company.

  • GE HealthCare stock falls on Q1 revenue miss

    GE HealthCare Technologies' (GEHC) shares experienced a sharp decline in Tuesday's afternoon trading session, as the company's first quarterly report since its 2023 spinoff from General Electric fell short of revenue estimates. The company saw revenue drop 1% year-over-year, fueling a sell-off among investors. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the report. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith

  • Walmart shuttering health units, including telehealth and 51 clinics

    Walmart announced it is closing down its healthcare business Tuesday. The move will impact 51 locations in five states, as well as relationships with health systems, like the one penned with Florida's Orlando Health in November.

  • Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024

    Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.

  • How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk

    The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?

  • AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

    AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.

  • Walgreens launches specialty pharmacy unit to compete in new PBM era

    Walgreens is launching new services and consolidating specialty services to compete in the pharmacy benefits management (PBM) space.

  • ImmunityBio's bladder cancer therapy wins FDA approval

    The US Food and Drug Administration has approved ImmunityBio's (IBRX) bladder cancer therapy, a significant milestone for the company. ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong, joins Market Domination alongside Yahoo Finance's health reporter Anjalee Khemlani to discuss the company's plans following this pivotal approval. Soon-Shiong says that Anktiva will be "the next generation of immuno-therapy." He claims the drug is the first of its kind to "generate complete remission that's completely durable" for 47 months and longer. Soon-Shiong believes the drug will serve as "a backbone" to "checkpoint inhibitors," a class of immunotherapy drugs. He envisions the drug's potential to target cancers regardless of their location within the body, describing it as "an opportunity to use this as a fundamental platform across all tumor types." Soon-Shiong says he, alongside other entities, collectively invested around $400 million in the company when the drug was first rejected. He further notes that additional investments totaling $100 million are forthcoming, stating, "the company is stable in terms of cash capabilities,"— hoping for a commercial launch of Anktiva in May. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith

  • J&J CFO: We've 'beefed up' cardiovascular medical devices in hopes of reviving our medtech business

    J&J is doubling down on medtech, a typically sleepy sector that has been risky, as it looks to grow after spinning of consumer health segment Kenvue.

  • Walgreens CEO: 'We are on a mission to achieve provider status for our pharmacists'

    Walgreens is in the middle of a turnaround strategy. CEO Tim Wentworth sat down with Yahoo Finance to discuss the company's new focus.

  • Walgreens aims to deliver value as consumers seek relief: CEO

    Despite beating analyst expectations on both revenue and earnings in its latest second quarter results, Walgreens Boots Alliance (WBA) narrowed its Adjusted EPS guidance for fiscal year 2024, citing a challenging retail environment. Walgreens CEO Tim Wentworth joins Yahoo Finance Live to shed light on the factors that prompted the decision. Wentworth emphasizes that the "real dynamic" is the strain faced by consumers under current economic conditions. He highlights that consumers are seeking value, and Walgreens is focused on delivering that with the continued sensitivity around pricing. Reflecting on the company's pharmacy business, Wentworth admits that it experienced "a challenging time." However, he states that they have since been able to secure adequate staffing and forge relationships with pharmacy schools to bolster hiring efforts: "We like where we are now." Wentworth explains that the company's efforts extend beyond hiring, but rather "work redesign," allowing pharmacists to "operate at the very top of their clinical ability." Wentworth attributes the negative outlook surrounding Pharmacy Benefit Managers (PBMs) to "consumer, patient dissatisfaction with the way the system works." However, he views this as "an opportunity" to help reshape this outlook. He emphasizes that by concentrating on areas such as value and transparency for consumers, they can aid in transforming this perception, posing the question, "What's the model for the future that's gonna help a PBM help its consumer?" For more expert insight and the latest market action, click here to watch this full episode of Wealth! Editor's note: This article was written by Angel Smith

  • Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data

    Viking Therapeutics is gearing up to compete with market GLP-1 leaders Novo Nordisk and Eli Lilly.

  • Amid increased federal scrutiny, PBMs pivot strategy to further squeeze independent pharmacies

    PBMs have used various strategies over the years to squeeze independent pharmacies, and these tactics are on the rise as the federal government takes aim at reigning in the notorious middlemen.

  • Moody's says will be 'many years' before big AI impacts are seen in healthcare, pharma

    Moody's says pharma and medical device companies are most likely to see the earliest benefits from adopting AI technology.

  • UnitedHealth Group top pick despite cyberattack and DOJ setbacks: BofA

    UnitedHealth Group's recent cyberattack and DOJ probe are unlikely to be long-term headwinds, according to a BoA analyst.

  • UnitedHealth's cyberattack should be a 'wake-up call' for healthcare

    UnitedHealth Group faced a cyberattack that froze an important subsidiary in the healthcare ecosystem.